Premium
Moving toward a more rational, evidence‐based approach to PSA screening, diagnosis, and treatment of prostate cancer
Author(s) -
Filson Christopher P.
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31332
Subject(s) - medicine , prostate cancer , incidence (geometry) , prostate , prostate specific antigen , cancer , prostate cancer screening , oncology , gynecology , physics , optics
Screening with prostate‐specific antigen (PSA) has decreased since recommendations against its use in 2012, with some claims of subsequent and related increase in metastatic prostate cancer incidence. Competing trends and alternative hypotheses should be investigated before accepting a direct link between a decrease in PSA screening and rise in metastatic prostate cancer. See also pages 2733‐9.